- Home
- SMBK vs ABVX Comparison
SMBK vs ABVX Comparison
Compare SMBK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- ABVX
- Stock Information
- Founded
- SMBK N/A
- ABVX 2013
- Country
- SMBK United States
- ABVX France
- Employees
- SMBK N/A
- ABVX N/A
- Industry
- SMBK Major Banks
- ABVX
- Sector
- SMBK Finance
- ABVX
- Exchange
- SMBK Nasdaq
- ABVX Nasdaq
- Market Cap
- SMBK 521.4M
- ABVX 451.5M
- IPO Year
- SMBK N/A
- ABVX N/A
- Fundamental
- Price
- SMBK $31.55
- ABVX $6.35
- Analyst Decision
- SMBK Buy
- ABVX Buy
- Analyst Count
- SMBK 5
- ABVX 4
- Target Price
- SMBK $34.40
- ABVX $31.50
- AVG Volume (30 Days)
- SMBK 50.0K
- ABVX 199.6K
- Earning Date
- SMBK 07-21-2025
- ABVX 03-24-2025
- Dividend Yield
- SMBK 1.01%
- ABVX N/A
- EPS Growth
- SMBK 44.84
- ABVX N/A
- EPS
- SMBK 2.26
- ABVX N/A
- Revenue
- SMBK $171,664,000.00
- ABVX $11,172,999.00
- Revenue This Year
- SMBK $20.95
- ABVX $284.20
- Revenue Next Year
- SMBK $9.48
- ABVX N/A
- P/E Ratio
- SMBK $13.96
- ABVX N/A
- Revenue Growth
- SMBK 16.34
- ABVX 135.94
- 52 Week Low
- SMBK $21.40
- ABVX $4.77
- 52 Week High
- SMBK $37.72
- ABVX $14.71
- Technical
- Relative Strength Index (RSI)
- SMBK 53.26
- ABVX 53.40
- Support Level
- SMBK $30.68
- ABVX $5.59
- Resistance Level
- SMBK $32.27
- ABVX $6.09
- Average True Range (ATR)
- SMBK 0.58
- ABVX 0.32
- MACD
- SMBK -0.05
- ABVX 0.02
- Stochastic Oscillator
- SMBK 43.87
- ABVX 86.36
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.